Director of the USPTO
Under Secretary of Commerce for Intellectual Property
David Kappos is the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office. In this role, he advises the President, the Secretary of Commerce, and the Administration on intellectual property matters. Over a 20-year career in intellectual property, Mr. Kappos has accrued deep knowledge of the intellectual property system and broad respect from professionals across the field. Mr. Kappos directs an office that provides incentives to encourage technological advancement and helps businesses protect their investments, promote their goods and services and safeguard against deception in the marketplace. The Office continues to deal with a patent application backlog of more than 700,000, long waiting periods for patent review, information technology systems that are regarded as outdated and an application process in need of reform.
United States Circuit Judge
Sharon Prost was appointed by President George W. Bush in 2001. Prior to her appointment, Judge Prost served as Minority Chief Counsel, Deputy Chief Counsel, and Chief Counsel of the Committee on the Judiciary, United States Senate from 1993 to 2001. She also served as Chief Labor Counsel (Minority), Senate Committee on Labor and Human Resources from 1989 to 1993. She was Assistant Solicitor, Associate Solicitor, and Acting Solicitor of the National Labor Relations Board from 1984 to 1989. She was an Attorney at the Internal Revenue Service from 1983 to 1984, and Field Attorney at the Federal Labor Relations Authority from 1980 to 1983. Judge Prost also served as Labor Relations Specialist/Auditor at the United States General Accounting Office from 1976 to 1980 and Labor Relations Specialist at the United States Civil Service Commission from 1973 to 1976. Judge Prost received a B.S. from Cornell University in 1973, an M.B.A. from George Washington University in 1975, a J.D. from the Washington College of Law, American University in 1979, and an LL.M. from George Washington University School of Law in 1984.
George C. Elliott, Ph.D.
Group Director, Technology Center 1600
United States Patent and Trademark Office
George C. Elliott is a Group Director in Technology Center 1600, which examines patent applications in biotechnology, organic chemicals and pharmaceuticals, at the United States Patent and Trademark Office. He joined the USPTO in 1989 and served as a patent examiner, primary examiner, supervisory patent examiner, biotechnology practice specialist and director of the Office of Patent Quality Assurance prior to being named a Group Director in 2005. Prior to joining the USPTO, Mr. Elliott received his Ph.D. in biology from the University of Utah and did post-doctoral research at Cambridge University and the University of California, Berkeley, working on mechanisms of mammalian DNA repair and replication. Mr. Elliott has spoken on aspects of biotechnology and patents at numerous meetings and venues, and has published articles on gene and pharmaceutical patenting issues.
Director of Phamacy, EPO
Dr. Dieter Tzschoppe, of French nationality, studied chemistry at the University of Stuttgart (Germany) and holds a PhD in organic chemistry from the University of Besançon (France). He joined the EPO in 1985 in The Hague (Netherlands) as Search Examiner in the field of pharmaceutical formulations. After his transfer to Munich (Germany) in 1989 he worked as search and substantive examiner in the field of medical use inventions. Since 1999 he is director of a unit of examiners, first in organic chemistry, and since 2005 in pharmacology in the cluster Pure and Applied Organic Chemistry.
Deputy Director-General of 3rd Examination Department
Japan Patent Office (JPO)
Mr. Satoshi MORIYASU is Deputy Director-General of 3rd Examination Department of Japan Patent Office (JPO). He joined the JPO in 1985 as a patent examiner. He served as various positions such as First Secretary of Japanese Mission in Geneva of Ministry of Foreign Affairs (1997-2000), Appeal Examiner of the JPO (2001-2003), Director of Multilateral Policy Office of the JPO (2004-2006), Director of 3rd Examination Department of the JPO (2007-2009), Director of International Affairs Division of the JPO (2009-2010), Senior Director of Medical Science Division of 3rd Examination Department of the JPO (2011).
State Intellectual Property Office of the PRC (SIPO)
Mr. Guiming Liu joined the State Intellectual Property Office of the PRC (“SIPO”) in 1991, responsible for the patent examination and management. He is currently the division director of the Chemistry Examination Department of SIPO. Mr. Liu is quite familiar with intellectual property protection mechanisms in China and relevant Chinese IP laws and regulations. He has rich experience in patent prosecution and IP protection in pharmaceutical sector, and in-depth knowledge on drug R&D and IP protection strategies of research-based pharmaceutical companies. He is in the expert panel of one of the PRC national study projects on IP development strategies: “National Pharmaceutical Intellectual Property Development Strategies”. He is the teacher and research supervisor of the Master’s Degree Program in International Pharmaceutical Engineering Management of Peking University, and the deputy chief editor of Technical Guidelines on the Patent Prosecution and IP Protection of Traditional Chinese Medicines.
Robert DeBerardine, JD
Vice President and Head of Global Patents
Robert DeBerardine is the Global Head of Patents for sanofi-aventis and is based in Paris. Mr. DeBerardine is responsible for all aspects of sanofi-aventis’ patent portfolio and patenting strategies. Mr. DeBerardine has an extensive background in all facets of intellectual property law having served as Chief Patent Counsel for Abbott Laboratories, Assistant Chief Patent Counsel for Johnson & Johnson and as a trial attorney litigating patent cases when he was a partner at the law firms of Brobeck, Phleger and Harrison and earlier with the law firm of Jones Day, Reavis and Pogue. Mr. DeBerardine has a Bachelors Degree in Chemical Engineering from Lafayette College and a Juris Doctor Degree from Cornell Law School.
Stuart Watt, JD
Vice President, Law and Intellectual Property Officer
Mr. Watt is Vice President, Law and Intellectual Property Officer of Amgen Inc. and leads a group of 45 patent attorneys responsible for patent strategy, filing and prosecution of patent applications in the U.S. and foreign countries, patent litigation, and patent licensing. Mr. Watt has actively represented Amgen in patent litigation in the U.S. and various countries around the world. He joined Amgen in 1992. Prior to that time, he was associated with the patent law firm of Richards, Medlock & Andrews (now Sidley & Austin) in Dallas, Texas. Mr. Watt is a graduate of Brigham Young University (B.S.Ch.E. 1983) and the University of Washington School of Law (JD 1986).
John D. Conway
Global Head of Innovative Healthcare Patent Support
John D. Conway is the Global Head of Innovative Healthcare Patent Support for Sanofi. Mr. Conway started his career as a patent agent at Pfizer where he continued to work as a patent attorney when he received his law degree. Mr. Conway worked for Beaufour-IPSEN and then BASF Bioresearch Corp. and experienced the cultures of the United States, France, and Germany that play such an important part of working at sanofi-aventis, now Sanofi Group. Mr. Conway joined Abbott Labs and headed the biotechnology patent team that was responsible for developing Humira, which is one of the world largest selling products. Mr. Conway works within the pharmaceutical areas of both small molecule chemistry and biologics. Mr. Conway is responsible for sanofi- aventis' entire innovative pharmaceutical patent portfolio. Mr. Conway has a Master Degree in Chemistry from State University of New York at Stony Brook and Juris Doctor Degree from Western New England College.
Thomas L. Irving
Tom Irving has some 36 years of experience in the field of intellectual property law in Finnegan’s D.C. and Belgian offices. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement, enforceability, and validity analysis in the chemical/pharmaceutical fields, as well as litigation. He has been involved as lead counsel in numerous patent interferences, reissues, and reexaminations, and has also served as an expert witness in patent litigation. Mr. Irving chaired American Intellectual Property Law Association, Chemical Practice Committee in 1991; and a Board member of Directors between 1992 to 1994. He has been co-chair in Howard University School of Law, Institute of Intellectual Property and Social Justice since 2008 to present.
Jennifer Swan focuses her practice on enforcing and defending patent rights for clients in the biotechnology and pharmaceutical industries, and has extensive experience in cases arising from the filing of Abbreviated New Drug Applications. Ms. Swan has been involved in all aspects of pre-trial, trial, and post-trial proceedings in federal district courts, including D. New Jersey, D. Delaware, E.D. Texas, E.D. Pennsylvania, and N.D. Illinois. In particular, Ms. Swan has unique experience concerning litigation practice in N.D. California, having clerked for two different judges in the district. Additionally, she has considerable experience in appellate proceedings at the U.S. Supreme Court and at the U.S. Court of Appeals for the Federal Circuit. Ms. Swan has also been involved in interference proceedings in federal district court and proceedings before the Federal Trade Commission.
Justin Hasford, JD
Director, Chemistry and the Law Partner Finnegan
Mr. Hasford is an attorney in the Chemical Practice Group of the Washington, DC Office of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Mr. Hasford's practice focuses on complex patent litigation on behalf of pioneer pharmaceutical companies, including litigation arising from Abbreviated New Drug Applications under the Hatch-Waxman Act. Mr. Hasford additionally has litigated health care business method patents. Mr. Hasford has served as Chair and Program Chair of the Division of Chemistry and the Law of the American Chemical Society, as well as liaison to the Committee on Patents and Related Matters. Mr. Hasford also serves as Deputy General Secretary of the Second Beijing International Pharmaceutical and Chemical Intellectual Property Forum.
Dr. Elizabeth Werner
Senior Intellectual Property Manager
Wisconsin Alumni Research Foundation
Dr. Elizabeth Werner is the Senior Intellectual Property Manager at Wisconsin Alumni Research Foundation (WARF). She actively manages the vitamin D portfolio which is both the largest portfolio and the most lucrative technology for WARF. She manages about 4,000 cases from 50 professors at UW-Madison as well as guest lectures in various classes. Topics of these lectures include alternative careers in science, the history and function of WARF and technology transfer, the patent process, different forms of protecting plant IP, and patents and clinical trials. Her portfolio spans technologies as diverse as plant varieties to medical devices. Prior to joining the WARF, Dr. Werner spent a number of years in the biotechnology industry managing intellectual property and licensing in technologies for strategic product development.
Dr. Jiang Hualiang
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Dr. Hualiang Jiang is currently a professor of Shanghai Institute of Materia Medica (SIMM), also assumes the deputy director of the institute and the director of the Drug Discovery and Design Center. Dr. Jiang received his Master degree in physical chemistry (quantum chemistry) in 1992 from East-China Normal University, and Ph.D. degree in organic chemistry from Chinese Academy of Sciences in 1995. He is the chief-scientist of one 973 project and acts as memberships for the scientific committee of several major research programs in China, such as 863 Program in Biology and Medical Technology, National Basic Research Program in Protein Science, and Major Research Project of the National Natural Science Foundation. He also serves on the Editorial Advisory Boards for several journals like Journal of Medicinal Chemistry and ChemMedChem. He has been rewarded by Natural Sciences Award of China, 5th Prize of Yong Scientist Awards of China,Natural Sciences Award of Shanghai, and Top-10 Outstanding Scientist of Shanghai (2001-2003).
Dr. Joseph P. Taormino
B.A. Chemistry, molecular biologist, European Patent Attorney
Dr. Joseph P. Taormino is partner of Hoffmann Eitle, a Co-leader of the Biotech Group. Dr. Taormino has been a European Patent Attorney since 1998, specialized in opposition and appeal proceedings before the European Patent Office; legal opinions and litigation in the fields of biotechnology and pharmaceuticals. Particular experience with patents/applications relating to genes, proteins, transformed eukaryotic and prokaryotic cells, transgenic animals and plants and in vitro screening and diagnostic methods. Involved in opposition/appeal proceedings on erythropoietin (T412/93), antisense RNA (T994/95), reach-through claims (T609/02), “Housey” (T729/00), hepatitis C (T1399/04) and anti-TNF mAbs (T601/05) among others; cross-border litigation on alpha-interferon and involvement in several due diligence evaluations on the IP assets of established biotech firms and start-ups.
Dr. Armstrong is a partner of Birch, Stewart, Kolasch & Birch, LLP. BSKB is one of the leading law firms in US patent prosecution. Dr. Armstrong's practice includes the preparation and prosecution of patent applications dealing with diverse technologies, including pharmaceutical chemistry, immunology, biotechnology, organic chemistry, diagnostic assays and drug screening systems. Her practice also includes the preparation of due diligence and FTO opinions regarding issues of patentability, validity, infringement, and exemptions from infringement. Dr. Armstrong also has experience with FDA matters, including Patent Term Extension and Orange Book Listings and ANDAs/Paragraph IV certifications. Dr. Armstrong lectures around the world on patent matters. She is also a past member of the Advisory Committee for the Joint Commission of Science and Technology for the Virginia General Assembly.
Director, Head of Patents, ECSF
Principal, Spruson & Ferguson
Kristian is a Director of Ella Cheong Spruson & Ferguson and a Principal of associated Australian firm, Spruson & Ferguson, based permanently in Singapore where he is Head of the Patents group. He is also the current President of the Association of Singapore Patent Agents, a professional society which represents and promotes the interest of the Singapore Patent Agent profession. Kristian has considerable experience in patent revocation practice before the Intellectual Property Office of Singapore (IPOS) and successfully represented the Applicant for revocation in the inaugural revocation proceedings before IPOS. His practice primarily involves the preparation, drafting and prosecution of patent applications, advice in relation to patent validity and enforcement, patent strategy, patent revocation actions, and patent infringement advice, also involved in advising clients in connection with patent litigation actions in the Singapore High Court.
Dr. Andrew Blattman
Principal, Spruson & FergusonDirector
Dr. Andrew Blattman is a Principal of Spruson & Ferguson’s Chemical/Life Sciences patent team and a Director of Ella Cheong Spruson & Ferguson. He specialises in biotechnology, working with several of Australia’s major universities and research institutes. He has particular expertise in identifying, protecting and advancing IP rights in the fields of genetics and molecular biology. Dr. Blattman is a co-author of the Biotechnology IP Management Manual commissioned by the Australian government agency, Biotechnology Australia, and the author of a number of research articles in international journals, scientific conference papers, monographs and book chapters.
Jay J. KIM
Attorney (Admitted in New York)
Jay J. Kim is a U.S. licensed attorney at Kim & Chang specializing in intellectual property, product liability, pharmaceuticals, chemicals and energy. Mr. Kim has been admitted to the New York and U.S. Patent Bars, and is also licensed as a Professional Chemical Engineer. Mr. Kim specializes in civil and criminal IP disputes, patent litigations, along with IP prosecution, transactions and portfolio management. Mr. Kim also counsels clients in product liability litigation, and various issues related to the pharmaceutical, chemical and energy industries.
Dr. Barbara Rudolph
Barbara Rudolph heads Finnegan’s biotechnology and pharmaceutical practice group. She focuses her practice primarily on Hatch-Waxman Paragraph IV Abbreviated New Drug Application (ANDA) and biotechnology litigations, as well as other pharmaceutical and biotechnology-related disputes. She has experience in bench and jury trials in federal district courts and has argued cases before the U.S. Court of Appeals for the Federal Circuit. She also provides strategic pre-litigation client counseling, due diligence analyses, and opinions. For the past 15 years, Ms. Rudolph has represented pharmaceutical and biotechnology companies on matters involving blockbuster drugs and has has helped protect clients’ valuable intellectual property in sophisticated technologies
Chemistry and the Law
Sarah Hasford is a member of the Intellectual Property group at McGuireWoods, LLP in Tysons Corner, Virginia. Sarah attended law school at the University of New Hampshire School of Law (formerly Franklin Pierce Law Center) and earned her B.S. in Chemistry from Union University in Jackson, Tennessee. Prior to joining McGuireWoods, Sarah was an Associate at Connolly Bove Lodge & Hutz LLP in Washington, D.C. and worked as a Patent Examiner examining patent applications directed to heterocyclic organic compounds at the U.S. Patent and Trademark Office. While in law school, Sarah also externed for the Honorable Arthur J. Gajarsa at the United States Court of Appeals for the Federal Circuit.
Philip L. Hirschhorn, JD
Buchanan Ingersoll & Rooney PC
Philip L. Hirschhorn is the Patent Litigation team leader for the Intellectual Property Practice Group. He is an intellectual property litigator who focuses his practice on patent and trade secret litigation. Phil has extensive trial and client counseling experience, with particular emphasis on representing clients in the pharmaceutical, medical device, computer and consumer products industries. He also has experience handling copyright and trademark/trade dress litigation. Recently, Phil has tried cases involving computer graphics hardware and defending a major pharmaceutical company's patent rights from infringement by generic manufacturers. Phil has a Bachelors Degree from Columbia College and a Juris Doctor Degree from Fordham University School of Law.
Before joining ChemPartner, Dr. Yuguang Wang worked at Schering-Plough for 19 years and held the position of Associate Director of Discovery Chemistry. He was awarded with three Schering-Plough Discovery President’s Awards, one Schering-Plough Impact Award, and one Schering-Plough Special Recognition Award.
Dr. Wang was also recognized by the research community outside Schering-Plough. He was the recipient of the 2008 Thomas Edison Patent Award by the New Jersey Research and Development Council. He has a Ph.D. in Organic Chemistry from The University of Kansas. Dr. Wang is the inventor of 19 authorized patents and has issued 24 research publications.
Dr. Leo Polz
Dr. Leo Polz is partner of Hoffmann Eitle. His main areas of practice cover patent prosecution, opposition, appeal and revocation proceedings before the German and European Patent Office, patent infringement litigation both national and cross-border, due diligence, opinion work and client counseling. IP experience with Japan and China. Special interest in pharmaceutical and biochemistry, also paper chemistry. Litigation practice with pharmaceutical, cosmetical and food-stuff patents, inter alia Factor VIII, PCR, Viagra and embryonic stem cells. Dr. Polz is also a frequent speaker throughout Europe and the USA on questions of German and European Patent Law, in particular in the field of Biotechnology.
Dr. Marinda Li Wu
American Chemical Society
Dr. Marinda Li Wu has over thirty years of experience working in the chemical industry, she enjoyed many years working for Dow Chemical R&D as well as Dow Plastics Marketing forging partnerships between industry, education, government and communities. An ACS member for over forty years, Dr. Wu has served in many leadership roles at both the local and national levels. She served her local section over the last twenty years as Chair of the California Section during its 100th Anniversary, National Chemistry Week Coordinator as well as Committee Chair for Public Relations, Women Chemists, Government Affairs, and Local Section Career Program Coordinator. She passionately promotes STEM education and public outreach and initiated popular programs for her local section such as Family. Science In 2011, she was elected to the Presidential succession of the American Chemical Society.
Stephen Bennett is a partner in Hogan Lovells' Intellectual Property practice and is based in London. He specializes in patents, confidential information and regulatory aspects of pharmaceutical product exclusivity. Stephen acts for innovator drug companies in patent disputes with generic drug companies and in supplementary certificate (SPC) disputes. His work involves developing and co-ordination of strategies in anticipation of generic product launch on a European basis. His patent litigation work includes the following: defending ZOCOR (simvastatin) and FOSAMAX (alendronate) from generic attack; obtaining the first ever “zero term” SPC (JANUVIA); obtaining the first European pediatric extension of an SPC (on COZAAR); defending GEMZAR (gemcitabine) from generic attack; obtaining interim injunction against the launch of generic SUSTIVA (efavirenz).
Mr. Bert Oosting is Partner of Hogan Lovells and a member of its Intellectual Property Steering Committee and the Life Sciences Core Team. His practice encompasses all areas of Intellectual Property, Patents and Life Sciences, advises on patent strategy, patent prosecution and enforcement strategies, as well as transactional matters such as technology transfers and licensing. Bert has vast experience in patent litigation in all relevant technical areas, but with a specialization in pharmaceuticals, biotechnology and the medical devices industry. Bert not only handles patent cases before the courts in the Netherlands, but has also been involved in oppositions before the European Patent Office. He also regularly lectures on these areas of law and is a prolific writer and speaker on this topic.
Patent Attorney, Vice President
NTD Patent & Trademark Agency LTD
Ms. Heather Lin is Vice President of NTD Patent & Trademark Agency Ltd. She represents a full range of clients, from start-ups to multinational companies, and her practice primarily involves patent drafting and prosecution, patent infringement and validity opinions and lawsuits, and client counseling in IP strategic planning and portfolio management, with an emphasis in the areas of biotechnology and pharmaceuticals. Ms. Lin is a frequent speaker in various IP forums and conferences, and she is also the contributor of the China chapter of Biotechnology and Pharmaceutical Patents: Law and Practice (Aspen Publishers, Wolters Kluwer Law & Business, 2008, USA). Ms. Lin is a member of All-China Patent Agents Association (ACPAA), Council Member of AIPPI China Group and member of LES.
Yeda Research and Development LTD
Gil Granot-Mayer has been serving as the General Counsel of Yeda Research and Development LTD (The commercial arm of the Weizmann Institute of Science in Israel) since 2006, is a senior member of the executive team of the company. As General Counsel of Yeda, he has negotiated over 100 licensing deals in various technological areas (Pharmaceuticals, biotechnology, energy, clean-tech, research devices, medical devises, materials and more) and has led the litigation activities of the company including multinational patent litigation and licensing disputes. Gil holds an MBA degree from the Tel-Aviv University, the Leon Recanati Graduate School of Business Administration, and an LL.B. degree (cum laude) from Tel-Aviv University. Gil Granot-Mayer is a member of the Israeli Bar Association since 1997.
Simmons & Simmons China
Lewis Ho is a Partner in the intellectual property practice at Simmons & Simmons (Beijing Office). He has a broad range of experience in intellectual property across various industries, including life sciences. Mr. Ho has represented various international pharmaceutical companies setting up R&D centers, and has negotiated more than 35 joint-venture, collaboration and outsourcing projects with Chinese corporations, academic institutes, hospitals and contract research organizations in the last two years. Lewis is recognized as one of the leading IP and life sciences lawyers in China. He is recognized by Chambers Asia and Legal 500 and named by IAM as one of the leading 250 patent litigators, life sciences litigator and licensing lawyers in the world. He was the Vice-chairman of the IP Working Group (Shanghai) of the European Union Chamber of Commerce in China (2009 - 2011). He is also the Honorary Legal Advisor of HKAPI, the trade association representing research-based pharmaceutical companies in Hong Kong.
Head of Intellectual Property Rights
Bayer (China) LTD
Since January 2008 Oliver Lutze heads the IPR function of the Corporate Legal Department for all Bayer Group Companies in Greater China. In his function he is responsible for patent, trademark and copyright matters. He has a special expertise in the prosecution and defense of life sciences patents, advising on China R&D related topics and employee’s remuneration law. Oliver is with Bayer since 1998. Before he came to China he served as Senior IP Counsel in the Bayer headquarter. Oliver is qualified to practice as European and German Patent Attorney.
Ningling Wang’s practice involves patent prosecution, opinions, due diligence, client counseling, licensing, and patent litigation in the areas of chemicals, chemical engineering, pharmaceuticals, medical devices, semiconductor materials, and nanotechnology. She has extensive experience working with multinational and Chinese companies, providing legal advice on IP portfolio management and due diligence. Ms. Wang has been involved in various cases before the U.S. International Trade Commission (ITC) and U.S. district courts. Ms. Wang speaks frequently in conferences and seminars in China and internationally on patent-related topics. She taught a graduate course on U.S. IP law at Renmin University of China Law School and a graduate course on U.S. IP law, with patent mock trial, at Shanghai Jiao Tong University KoGuan Law School. She also serves as a program professor of Law at China Science and Technology University.
Dr. Jianzhong (David) Shen is a regional legal counsel at AstraZeneca. His primary responsibilities include enforcing AZ’s IP rights in Asia, advising the company on legal issues related to the commercial activities in China, and supporting AZ’s R&D efforts in Asia. Before joining AZ, Dr. Shen was the Asia regional patent counsel at Eli Lilly and worked as a patent attorney for seven years at AstraZeneca Pharmaceuticals in the U.S. Dr. Shen received his J.D. degree from Temple University School of Law and his Ph.D. degree in Chemistry from Cornell University. He is licensed to practice before the United States Patent and Trademark Office and in the States of Pennsylvania and New Jersey.
Liu, Shen & Associates
Amy joined Liu Shen in 1996 and now has more than 16 years’ experience in the field of IP law. Ms. Feng specializes in all phases of patent prosecution, reexamination, patent invalidation, and patent litigation and counseling, including infringement as well as validity analysis in the chemical and biotech fields. She is a member of the China Law Society, the Chinese Group of AIPPI, and the Chinese Patent Agents Association. Ms. Feng has lectured in dozens of European and US transnational chemical and pharmaceutical and biotech companies. She has also published numerous articles in the edition of China IP Focus China 2007 and Managing Intellectual Property.
Dr. Dominique Kugel
Head of Therapeutic Strategy Units
Dr Dominique Kugel is the Head of Therapeutic Strategy Units within the patent department of Sanofi in Paris. She is responsible for R&D support in specific pharmaceutical areas but also handles European patent litigations. Her career started with Marion-Merrell Dow as a chemist and then as a patent trainee. She thereafter joined the patent department of Synthelabo (now Sanofi). Ms Kugel has a PhD in Chemistry from the University of Strasbourg (France) and is qualified as a European and French Patent attorney.
Yang is currently the Chief Patent Counsel of Simcere Pharmaceutical Group. Previously, he worked at Boston Biomedical Inc., ArQule, Inc., and Merck & Co., Inc. Yang’s legal experiences include patent strategy, patent prosecution, IP due diligence, and IP litigation. Yang received his JD degree from the University of Texas Law School, his PhD degree in Biochemistry and Molecular Biology from the University of Chicago, and his BS degree from Beijing University. Yang is registered to practice before United States Patent and Trademark Office, and admitted to practice in Massachusetts.
Peter L. Dolan
Head of Patent Support for Asia Pacific
Sanofi-aventis Singapore Pte. Ltd
Peter is Head of Patent Support for China, India, Japan and the Asia Pacific region at Sanofi, a leading global pharmaceutical company with over 100,000 employees worldwide. He has a B.Sc. (Hons) from University College Dublin, Ireland, a Doctorate degree in Chemistry from Oxford University, U.K. and a Law degree from Temple University, USA.. Peter is also a registered US Patent Attorney. Before joining the patent department at sanofi-aventis, Peter worked in the patent department at Rhone-Poulenc Rorer and DuPont Pharmaceuticals, as well as a large UK Patent firm. Peter has over 16 years of patent experience in the areas of global patent litigation, patent prosecution, product lifecycle management, licensing, due diligence and counseling clients on patent matters including patent procurement and litigation strategies. He is also a member of the Chartered Institute of Patent Agents (U.K.), Licensing Executive Society (Singapore) and the American Bar Association.
Chief Scientific Officer
Hua Yang is Chief Scientific Officer at Pharmaron. In this role, he oversees drug discovery services at Pharmaron. Prior to Pharmaron, he worked at AstraZeneca in neuroscience and pain management area as an assistant director for medicinal chemistry and a project leader for drug hunting projects.
Tao Guo, PhD
Medicinal Chemistry of WuXi AppTec, Inc
Tao Guo, PhD, is the Vice President of Medicinal Chemistry of WuXi AppTec, Inc. From 1992 to 1995, he worked at Ariad Pharmaceuticals as Senior Research Scientist and from 1995 to 2008 he was employed at Pharmacopeia as Director of Chemistry where he led a team of researchers in drug discovery for potential treatments for Alzheimer’s disease, metabolic disease, inflammatory disease, schizophrenia, cancer, infertility, and graft-versus-host disease as well as the application of combinatorial chemistry and structure-based design to facilitate drug discovery. He is an inventor of one Phase III clinical compound, one Phase II clinical compound, and five preclinical development candidates. He is the recipient of 21 issued US patents and an author of over 50 publications. He has served on the NIH Expert Review Panels, the Princeton ACS Fall Organic Chemistry Symposium Organizing Committee, the Editorial Board of ChemTracts – Organic Chemistry, and he is the President and CEO of the CGP-Doering Foundation. Dr. Guo joined WuXi AppTec in December 2008 and he has managed a wide range of medicinal chemistry programs with collaboration partners including big pharmas and biotechs. Dr. Guo received the Shanghai inaugural “Thousands Plan” award in 2011.
Yongkui Sun, Ph.D.
DPS China Operations
MSD R&D (China)
Dr. Yongkui Sun, a Caltech Ph.D. in chemistry, is Executive Director, China Operations, Discovery and Preclinical Sciences, MSD R&D (China). Dr. Sun has over 19 years of process development experiences at Merck. He led several Merck initiatives including the Catalysis Initiative, aiming at speeding up drug deliveries at early phase of drug development to enable toxicological evaluation of drug candidates, at designing efficient, green, and robust manufacturing process, and at enabling rapid access to complex and novel molecular structures for drug discovery. He spearheaded Merck's effort to identify catalysis needs in medicinal chemistry, communicated the needs to the scientific community, and led Merck's collaboration with academics and technology companies to address the top chemistry needs. Dr. Sun has authored 70 publications, was a recipient of the Thomas Edison Award in 2009, and the Presidential Green Chemistry Challenge Awards in 2005 and in 2006. He is a Presidential Fellow of Merck Research Laboratories.
Mark Chilung Tang, Ph.D. MBA
World Tech Ventures, LLC
Dr. C. Mark Tang is currently head of of WT Global Capital Inc, and Chairman of GCA Therapeutics, Ltd. He is an entrepreneur, educator, and a life science and high tech investment banker. Dr. Tang has co-founded three successful ventures. Most recently he was a director and co-founder of a digital right management tech company which was acquired by a public company (NASDAQ: RNWK). Dr. Tang has previously worked in Wall Street in different capacities including equity research, investment banking, and asset management for over 15 years at major investment banks. Dr. Tang is a co-founder and Chairman of the World Bio-technology Forum, through which Dr. Tang has provided educational conferences regarding bio entrepreneurship and venture financing in US and Asia. Dr. Tang has published two books and contributed regularly to international trade publications. He is also a frequent international speaker on various investment topics in US and China. From 2004-2006, Dr. Tang was also an instructor and biotech director at Rutgers Business School, where he taught biotech finance, venture capital and business development courses. Dr. Tang was one of the first identifying Asia biotech as a growth area, wrote one of the first article on biotech equity risk management and one of the first book on investing in biotech sector. Dr. Tang had been an advisor for non-profit and science park in Asia.